ROCHE HLDGS AG SPN ADR EACH REP 0.125GENUS (RHHBY)

31.87
0.06 0.18
OTC
Prev Close 31.93
Open 31.78
Day Low/High 31.76 / 31.91
52 Wk Low/High 29.89 / 35.13
Volume 1.05M
Exchange OTC
Shares Outstanding 5620.50B
Market Cap 177.38B
Div & Yield N.A. (N.A)

Latest News

Roche Receives CLIA Waiver For Cobas® Influenza A/B & RSV Test For The Cobas® Liat®

Roche Receives CLIA Waiver For Cobas® Influenza A/B & RSV Test For The Cobas® Liat®

The first CLIA-waived, real-time PCR test that differentiates flu and RSV in 20 minutes is available now for use in physician offices and urgent care settings

Biogen Should Either a Buyer or a Seller Be

Biogen Should Either a Buyer or a Seller Be

The company sans CEO Scangos needs to do some type of deal in the coming months.

Genentech Provides Update On Phase III Study Of Gazyva® In People With Previously Untreated Diffuse Large B-Cell Lymphoma

Genentech Provides Update On Phase III Study Of Gazyva® In People With Previously Untreated Diffuse Large B-Cell Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III GOYA study evaluating Gazyva ® (obinutuzumab) plus CHOP chemotherapy (G-CHOP) in people with previously untreated...

Roche Receives FDA Approval For Use Of SurePath Preservative Fluid With Cobas HPV Test For Cervical Cancer Screening

Roche Receives FDA Approval For Use Of SurePath Preservative Fluid With Cobas HPV Test For Cervical Cancer Screening

Roche HPV test is first to be approved for use with the SurePath Preservative Fluid gynecologic cell collection medium commonly used for Pap tests

Assessing the Impact of Juno's Cancer CAR-T Stumble on Biotech Stocks

Assessing the Impact of Juno's Cancer CAR-T Stumble on Biotech Stocks

Juno Therapeutics reminds investors yet again that the business of biotech -- developing new medicines that are effective and reasonably safe -- is hard to get right.

FDA Approves Genentech's Xolair® (omalizumab) For Allergic Asthma In Children

FDA Approves Genentech's Xolair® (omalizumab) For Allergic Asthma In Children

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Closing Bell: Humana Slumps on Deal Worries; U.S. Stocks Mixed

Closing Bell: Humana Slumps on Deal Worries; U.S. Stocks Mixed

A sharp selloff in crude kept stocks mostly in the red, though optimism ahead of Friday's jobs reports kept losses to a minimum on Thursday.

Medivation Shares Spike as Company Opens Door to Full-Fledged Auction

Medivation Shares Spike as Company Opens Door to Full-Fledged Auction

The company's shares were up nearly 2% in after hours trading.

Instead of Panicking on Brexit, Buy These Stocks

Instead of Panicking on Brexit, Buy These Stocks

Great Britain's decision to leave the European Union may alter the way Europe does business, but U.S. investors should not view it as a complete game changer.

FDA Grants Priority Review For Genentech's OCREVUS™ (ocrelizumab) Biologics License Application

FDA Grants Priority Review For Genentech's OCREVUS™ (ocrelizumab) Biologics License Application

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.

Roche Receives FDA Clearance For Its Procalcitonin (PCT) Assay To Help Clinicians Effectively Assess Sepsis Risk And Manage Sepsis Patients

Roche Receives FDA Clearance For Its Procalcitonin (PCT) Assay To Help Clinicians Effectively Assess Sepsis Risk And Manage Sepsis Patients

First IVD company to provide a fully integrated solution for PCT testing with Elecsys BRAHMS PCT

BioMarin Takeout Rumors Swirl, Industry Insiders Aren't Convinced

BioMarin Takeout Rumors Swirl, Industry Insiders Aren't Convinced

While some say Sanofi could make a bid for BioMarin, analysts aren't so convinced.

Merck Extends Cancer Immunotherapy Reach to First-Line Lung Cancer

Merck Extends Cancer Immunotherapy Reach to First-Line Lung Cancer

Merck's flagship cancer immunotherapy Keytruda delayed the re-growth of tumors and prolonged survival in patients with newly diagnosed non-small cell lung cancer compared to chemotherapy, the company said Thursday.

Cancer Drug Stocks: The Winners and Losers From ASCO 2016

Cancer Drug Stocks: The Winners and Losers From ASCO 2016

A summary (and somewhat subjective) breakdown of winners and losers from the American Society of Clinical Oncology annual meeting.

Phase III Study Shows Genentech's Actemra® (tocilizumab) Maintained Steroid-Free Remission in People With Giant Cell Arteritis (GCA)

Phase III Study Shows Genentech's Actemra® (tocilizumab) Maintained Steroid-Free Remission in People With Giant Cell Arteritis (GCA)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III study known as GiACTA, which evaluated Actemra ® (tocilizumab) in people with giant cell...

Genentech's Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Shrank Tumors In People With Previously Untreated Advanced Bladder Cancer

Genentech's Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Shrank Tumors In People With Previously Untreated Advanced Bladder Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that in a Phase II study, IMvigor 210, TECENTRIQ™ (atezolizumab) shrank tumors (objective response rate, ORR) in 24 percent (n=28)...

FDA Grants First Liquid Biopsy Approval To The Roche Cobas® EGFR Mutation Test V2

FDA Grants First Liquid Biopsy Approval To The Roche Cobas® EGFR Mutation Test V2

Test can be used with either plasma or tumor tissue, as a companion diagnostic for non-small cell lung cancer therapy

Genentech's Gazyva® Showed Superior Progression-Free Survival Compared To Rituxan® In People With Previously Untreated Follicular Lymphoma

Genentech's Gazyva® Showed Superior Progression-Free Survival Compared To Rituxan® In People With Previously Untreated Follicular Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the pivotal Phase III GALLIUM study in people with previously untreated follicular lymphoma, the most common type of...

Roche Announces The First FDA-approved CMV Test For Use In Hematopoietic Stem Cell Transplant Recipients

Roche Announces The First FDA-approved CMV Test For Use In Hematopoietic Stem Cell Transplant Recipients

New test standardizes CMV testing for both solid organ and hematopoietic stem cell transplant recipients

Phase III Study Of Genentech's Alecensa® (Alectinib) Showed Superior Efficacy Versus Crizotinib In Japanese People With A Specific Type Of Lung Cancer

Phase III Study Of Genentech's Alecensa® (Alectinib) Showed Superior Efficacy Versus Crizotinib In Japanese People With A Specific Type Of Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that Alecensa ® (alectinib), an oral anaplastic lymphoma kinase (ALK) inhibitor, reduced the risk of disease worsening or death...

Roche Receives FDA Approval For Novel PD-L1 Biomarker Assay

Roche Receives FDA Approval For Novel PD-L1 Biomarker Assay

The VENTANA PD-L1 (SP142) Assay approved as a complementary diagnostic for TECENTRIQ™ (atezolizumab) immunotherapy

FDA Grants Genentech's Cancer Immunotherapy TECENTRIQ™ (atezolizumab) Accelerated Approval For People With A Specific Type Of Advanced Bladder Cancer

FDA Grants Genentech's Cancer Immunotherapy TECENTRIQ™ (atezolizumab) Accelerated Approval For People With A Specific Type Of Advanced Bladder Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Genentech Highlights Personalized Medicines And Cancer Immunotherapies At 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting

Genentech Highlights Personalized Medicines And Cancer Immunotherapies At 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced new results from 19 approved and investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) Annual...

US Insurance Coverage For Harmony Prenatal Test From Roche Expands To 200 Million Covered Lives

US Insurance Coverage For Harmony Prenatal Test From Roche Expands To 200 Million Covered Lives

In-network status for non-invasive prenatal test now includes four largest national private health plans and Medi-Cal

Sanofi Presses Medivation to Hold Talks After $9.3B Offer

Sanofi Presses Medivation to Hold Talks After $9.3B Offer

The French pharmaceuticals company takes its campaign to snare the oncology specialist public.

April 25 Premarket Briefing: 10 Things You Should Know

April 25 Premarket Briefing: 10 Things You Should Know

U.S. stock futures slide Monday while European and Asian shares slump ahead of rate-setting meetings this week of the Federal Reserve and the Bank of Japan.

Genentech To Present New Data At AAN Showing Superior Efficacy Of Investigational Medicine Ocrelizumab Versus Comparators On Disease Activity And Progression In Two Forms Of Multiple Sclerosis

Genentech To Present New Data At AAN Showing Superior Efficacy Of Investigational Medicine Ocrelizumab Versus Comparators On Disease Activity And Progression In Two Forms Of Multiple Sclerosis

Genentech, a member of the Roche group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from three Phase III studies of the investigational medicine OCREVUS™ (ocrelizumab) will be presented during the 68th...